Related by context. All words. (Click for frequent words.) 65 ARBITER 6 63 HALTS 62 ACCOMPLISH 62 Intervention Effectiveness 61 Platelet Inhibition 61 Acute Myocardial Infarction 61 Double Blind Placebo 61 Intervention Effectiveness CATIE 61 CABANA 60 Randomized Phase 60 Controlled Trial 60 Aggressive Reduction 60 ASTEROID 59 Prospective Randomized 59 Prospective Randomized Trial 59 Phase III AFFIRM 59 BOLDER 59 Randomized Clinical Trial 59 ExTRACT TIMI 59 Carotid Revascularization Endarterectomy vs. 59 ONTARGET 59 Glucosamine Chondroitin Arthritis 58 Multicenter 58 Prostate AdenoCarcinoma Treatment 58 Combination Treatment 58 ARBITER 58 Cardiovascular Outcomes 58 TRANSFORMS 58 Prospective Multicenter 58 Statistically Significant 58 Adenoma Prevention 58 Antihypertensive 58 Pooled Analysis 58 Meta Analysis 57 Cardiogenic Shock 57 Clinical Antipsychotic Trials 57 Randomized Evaluation 57 Acute Ischemic Stroke 57 Nymox NX 57 JAK Inhibitor 57 Oral Fingolimod 57 First Patient Enrolled 57 Prognostic Significance 57 International Verapamil SR 57 multicentre randomized 57 Randomized Double Blind Placebo 57 Clinical Trial Results 57 Sipuleucel T 57 Lipid Lowering Treatment 57 Randomized Double blind 57 RE LY 57 Stenting Trial 57 CARE HF 57 Multicenter Phase 57 Long Term Outcomes 57 RADIANT 57 SPARCL 57 Clinical Trial Data 57 Randomized Controlled Trials 57 Preclinical Study 56 Multicenter Trial 56 Dual Antiplatelet Therapy 56 Investigational Compound 56 FREEDOMS 56 Aortic Stenosis 56 Refractory Angina 56 Phase 2b Study 56 Placebo Controlled Trial 56 Initiated Phase 56 EURIDIS 56 Severe Sepsis 56 Fixed Dose 56 CLINICAL TRIALS 56 Evaluation WISE 56 Low Dose 56 BOLDER II 56 Combination REOLYSIN R 56 Cholesterol Levels SPARCL 56 Stent Thrombosis 56 Clinical Efficacy 56 Randomized Trials 56 Cognitive Impairment 56 Elderly Patients 56 Diabetic Nephropathy 56 Rosuvastatin 56 Pharmacokinetic Study 56 Phase IIb Trial 55 Valsartan 55 Knee Osteoarthritis 55 STICH trial 55 Menopausal Women 55 Contraindications 55 Intervention Trial 55 Cholesterol Lowering Drug 55 Intervention Trial GAIT 55 Controlled Study 55 Pivotal Trial 55 Beneficial Effects 55 BARI 2D 55 RIO Lipids 55 Gene Variation 55 Gene Variants 55 CLARITY TIMI 55 Suicidality 55 HCV SPRINT 55 Ischemic Stroke 55 Confirmatory Phase 55 Study Evaluating 55 Double Blind Randomized 55 Pharmacokinetic PK 55 Ranolazine 55 Randomized Phase II 55 HEART FAILURE 55 Non Alcoholic Steatohepatitis 55 Subgroup Analysis 55 Meets Primary Endpoint 55 Beta Blocker 55 Patient Outcomes 55 Relapsing Multiple Sclerosis 55 fosbretabulin 55 Adjuvant Chemotherapy 55 ECASS 55 Unstable Angina 55 Val HeFT 54 CURRENT OASIS 7 54 Heart Failure Patients 54 Insulin Glargine 54 Asthma Intervention 54 ACCLAIM 54 Observational Study 54 Postmenopausal Women 54 Demonstrates Efficacy 54 phase IIIb 54 TAXUS ATLAS 54 Long Term Efficacy 54 Risk Stratification 54 Safinamide 54 Antipsychotic Drug 54 Randomized Study 54 Septic Shock 54 AND RECOMMENDATIONS 54 ORAL Sync 54 NSABP B 54 ADAGIO 54 MEND CABG 54 Inflammatory Markers 54 Fondaparinux 54 Carotid Endarterectomy 54 Endothelial Function 54 substudy 54 Phase 2b Clinical Trial 54 Bone Mineral Density 54 RE LY trial 54 II Clinical Trial 54 Postmarketing 54 subanalysis 54 ACCORD Lipid 54 STRIDE PD 54 Topics Covered Executive 54 ATACAND 54 Initiate Phase 54 RE MODEL 54 VICTOR E3 54 SCD HeFT 54 See CLINICAL PHARMACOLOGY 54 Brain Scans 54 Radiofrequency Ablation 54 VADT 54 Temsirolimus 54 Randomized Comparison 54 Coronary Artery Calcium 54 Antidepressant Use 54 Left Ventricular Dysfunction 54 Novel Oral 54 Patency 54 CLINICAL TRIAL 54 Thromboembolism 54 Inhaled Corticosteroids 54 Serious Adverse Events 53 PRECISE 53 Clinical Implications 53 Breaking Clinical Trials 53 Trandolapril 53 Gastric Cancer 53 Clinical Outcome 53 Stenting Trial CREST 53 Pivotal Phase 53 Coronary Revascularization 53 Dose Response 53 Microalbuminuria 53 Dose Escalation 53 AIM HIGH 53 STENT 53 Survival Benefit 53 BRIM3 53 Bosutinib 53 Sibutramine Cardiovascular Outcomes 53 TMC# C# 53 Patients Undergoing 53 Hypercholesterolemia 53 HYVET 53 Novel Mechanism 53 Autoimmune Disease 53 Ischemic 53 Randomized controlled 53 Monotherapy 53 Venous Thromboembolism 53 Phase Ib Clinical Trial 53 CABERNET 53 Systematic Review 53 Anti Tumor 53 Autologous Stem Cell Transplantation 53 Aortic Dissection 53 Nesiritide 53 Thiazolidinediones 53 Investigational Agent 53 GISSI 53 Prolongs Survival 53 Advanced Melanoma 53 ABCSG 53 Phase 1b Clinical Trial 53 Randomised 53 Glatiramer Acetate 53 Arch Neurol 53 Diastolic Heart Failure 53 Fungal Infections 53 Rosiglitazone Evaluated 53 PREDICTIVE 53 Aliskiren 53 Renal Cell Carcinoma 53 sorafenib Nexavar 53 Phase III Clinical Trial 53 Antiplatelet Therapy 53 Telmisartan 53 Investigational Drug 53 Hormone Refractory Prostate Cancer 53 NEVO RES 53 Orthostatic Hypotension 53 Tezampanel 53 Diagnostic Criteria 53 Pharmacokinetic 52 PREVENT IV 52 multicenter randomized controlled 52 Mimetics 52 Overactive Bladder 52 Randomized Double Blind 52 Tiotropium 52 Clinical Evaluation 52 MERLIN TIMI 52 randomized multicenter 52 CAVEATS 52 Oral Formulation 52 Carotid Stenting 52 Myocardial Infarction Study 52 COMPARE 52 J Clin 52 prospective multicentre 52 Drug Coated Stents 52 Novel Treatments 52 Reduce Cardiovascular 52 Edge STudy 52 Newly Diagnosed Multiple Myeloma 52 Hypertensive Patients 52 First Patient Dosed 52 Smooth Muscle 52 Multicenter Randomized 52 Neuroprotective Effects 52 randomized multicenter trial 52 HYPERTENSION 52 IN PATIENTS WITH 52 Hepatotoxicity 52 Skeletal Muscle 52 APRICOT 52 Long Term Survival 52 Multicenter Study 52 Blind Placebo Controlled Trial 52 PHASE III 52 Peginterferon Alfa 2a 52 AVERROES 52 RE LY ® 52 Surgical Treatment 52 PRoFESS 52 Adjuvant Therapy 52 Bile Acid 52 Data Suggest 52 Therapeutic Efficacy 52 Trial NLST 52 Placebo controlled 52 Dendritic Cells 52 By JENNIFER LEARN 52 Biological Effects 52 Schizophrenia Treatment 52 LUX Lung 52 ATTRACT 52 Therapeutic Arthritis 52 PROTECT AF 52 Adalimumab 52 Antitumor Activity 52 PFO migraine 52 Treatment Resistant 52 CALERIE 52 Genetic Variation 52 APPRAISE 52 multicenter randomized clinical 52 Late Breaker 52 Randomised Controlled Trial 52 Carotid Artery Stenting 52 Diabetic Macular Edema 52 Prevent Stroke 52 TO AVOID PREGNANCY WHILE 52 SABCS 52 controlled multicenter Phase 52 Arthritis Drugs 52 Multicentre 52 MERIT ES 52 Breast Cancer Recurrence 52 TRITON TIMI 52 AVAPRO 52 Well Tolerated 52 R lenalidomide 52 Kidney Transplant Patients 52 Pivotal Phase III 52 ILLUSTRATE 52 Placebo Controlled Study 52 Male Infertility 52 Targeted Therapy 52 Percutaneous Coronary Intervention 52 Preclinical Data 52 Diabetes Complications 52 Severe Asthma 51 Antiviral Activity 51 Avanafil 51 Effective Treatments 51 Teva Provides Update 51 THAT ARE DIFFICULT TO 51 Schiavo Autopsy 51 SORT OUT 51 NCCTG N# 51 Rotavirus Vaccine 51 Intracerebral Hemorrhage 51 Dose Ranging Study 51 Neuroprotection 51 COPERNICUS 51 Levels Linked 51 Prophylactic Treatment 51 Echocardiographic 51 Pulmonary Arterial Hypertension 51 Epilepsy Drug 51 Investigational Drugs 51 number NCT# ClinicalTrials.gov 51 Study Shows Significant 51 Stable Angina 51 J Am Coll 51 Genetic Markers 51 Attack Trial ALLHAT 51 CAPRIE 51 Systolic Hypertension 51 Reperfusion Injury 51 Prostate Cancer Progression 51 Proteinuria 51 DIAGNOSTIC 51 Myelofibrosis 51 Tyrosine Kinase Inhibitor 51 Clinical Trial Evaluating 51 Phase IIb Clinical Trial 51 Lupus Drug 51 Study Casts Doubt 51 Cholesterol Levels 51 #-# Full Text 51 #th Interscience Conference 51 Environ Health Perspect 51 ACTOS ® 51 SPIRIT FIRST 51 Cardiac Outcomes 51 APEX AMI trial 51 Receptor Antagonists 51 Anti Tumor Activity 51 Hematological Cancers 51 PUBLICATION OF 51 ST Segment Elevation 51 Advanced Renal Cell 51 Drug Candidate 51 Immunomedics Announces 51 Nicotine Vaccine 51 COVIDIEN 51 Amniotic Fluid 51 Aggressive Drug Evaluation 51 Phase IIIb 51 LENALIDOMIDE 51 Enoxaparin 51 Treatment Outcome 51 Relapsing Remitting Multiple Sclerosis 51 Venous Thrombosis 51 Remission Maintenance 51 Mechanistic 51 Acute Decompensated Heart Failure 51 NEW DRUG 51 Rheumatoid Arthritis Patients 51 Drug Shows Promise 51 Celecoxib APC trial 51 Submits NDA 51 IMPACT IMmunotherapy 51 Patients Treated With 51 Benign Prostatic Hyperplasia 51 Novel Inhibitor 51 Elevated Levels 51 Therapeutic Effects 51 brivaracetam 51 Cardiotoxicity 51 Reperfusion 51 FDA APPROVES 51 multicentre randomized controlled 51 Systemic Sclerosis 51 Reduced Risk 51 Inflammatory Arthritis 51 Lipid Levels 51 Statistically Significant Improvement 51 Outpatient Setting 51 nonrandomized studies 51 Histopathological 51 TIMI Study Group 51 evaluating mipomersen 51 Tipranavir 51 Initiates Phase III 51 Statin Drugs 51 Am J Clin 51 randomized Phase III 51 Randomized Controlled 51 Treatment Regimens 51 selenium supplementation 51 HORIZONS AMI 51 Tolvaptan 51 Allergic Rhinitis 51 Previously Treated 51 Digital Mammographic Imaging 51 Non Insulin Dependent 51 Often Misdiagnosed 51 Attenuates 51 Acute Coronary Syndrome 50 PreCISe 50 Renal Tumors 50 Treated Patients 50 Study Demonstrates 50 Improves Outcomes 50 Prostate Cancer Prevention 50 Iron Deficiency 50 Tanespimycin 50 PROactive study 50 Generalized Anxiety Disorder 50 imipramine Tofranil 50 PCI ExTRACT TIMI 50 immunomodulatory agents 50 CAMMS# 50 Prostate Lung Colorectal 50 Therapeutic Potential 50 dual endothelin receptor antagonist 50 Chicago Multidisciplinary Symposium 50 CombAT 50 STELLAR 50 J Natl Cancer Inst 50 PROactive Study 50 Pirfenidone 50 Asthma Treatment 50 PROactive 50 Effectively Treats 50 Pioglitazone 50 Drug Reactions 50 Survival Rates 50 Pediatric Patients 50 Histologic 50 Vitro Activity 50 multicenter multinational 50 Romiplostim 50 BCIRG 50 Zarnestra 50 Metabolic Disorder 50 Neoadjuvant Chemotherapy 50 Left Ventricular 50 Phase IIB 50 NIH Consensus 50 Gene Linked 50 Subtypes 50 Bucindolol 50 Heterozygous Familial Hypercholesterolemia 50 Ziprasidone 50 Endocrine Practice 50 Correlation Between 50 Help Predict 50 Pemphigus Vulgaris 50 Motility 50 Brain Stimulation 50 Peptic Ulcer 50 Confirmatory 50 Hepatocellular Carcinoma 50 Gene Silencing 50 Novel Antibiotic 50 Lung Injury 50 Thrombolysis 50 Study Validates 50 Antiepileptic Drug 50 Multicenter Randomized Double 50 Therapy Reduces 50 Observational Studies 50 Preliminary Findings 50 Laryngeal Cancer 50 Ambrisentan 50 Calcium Acetate 50 Phase III Clinical Trials 50 Ticagrelor 50 Dasatinib 50 Thromb Haemost 50 Shows Efficacy 50 AVADO 50 Drug Induced 50 unfractionated heparin UFH 50 Phase IIa Clinical Trial 50 subgroup analyzes 50 Arthritis Drug 50 MATCHED 50 Osteoporosis Drugs 50 Demonstrates Significant 50 Biomarker Study 50 AVANDIA 50 HDAC Inhibitor 50 Complicated Skin 50 Drug Fails 50 AEGR 50 HORIZONS AMI trial 50 Kinase Inhibitor 50 SYNTAX 50 Vildagliptin 50 Differential Diagnosis 50 Treprostinil 50 ARCOXIA 49 Efficacy Study 49 candesartan cilexetil 49 Ropinirole 49 Hedgehog Pathway 49 Eur J 49 Calcium Intake 49 Correlates 49 Acne Drug 49 Biochemical Zoology 49 Node Positive 49 Slow Progression 49 Contraceptive Use 49 Interferon Beta 49 Demonstrates Positive 49 Stent Placement 49 Chronic Heart Failure 49 Muraglitazar 49 Renal Function 49 Therapeutic Targets 49 Cinacalcet 49 Improved Survival 49 Inhaled Insulin 49 phase IIb clinical 49 Randomised Study 49 Rosiglitazone 49 BMC Musculoskeletal Disorders 49 #F FDG PET 49 Proves Effective 49 Anti Clotting Drug 49 Free Full Text 49 ENDEAVOR III 49 Rivaroxaban 49 Pharmacodynamics 49 Results Confirm 49 Lung Cancer Drug 49 Chronic Bronchitis 49 Progenitor Cells 49 Pafuramidine 49 Chronic Liver Disease 49 Cardiovascular Risk 49 CALGB # [002] 49 Vicriviroc 49 Prostate Cancer Therapy 49 RECORD1 49 CLOTS 49 Silicone Breast Implant 49 Antifungals 49 icatibant 49 FINDINGS 49 Demonstrates Potent 49 Advanced Neuroendocrine Tumors 49 Drug Eluting Stent System 49 Neurotoxicity 49 #:#-# [037] 49 Celebrex celecoxib 49 J Am Acad 49 multicenter prospective 49 multicenter phase 49 Predisposition 49 Multiple Ascending Dose 49 DOSAGE AND ADMINISTRATION 49 Insulin Sensitivity 49 Stress Hormone 49 longitudinal cohort study 49 Analytical Tool 49 ASCOT 49 MAGE A3 ASCI 49 Trial Evaluating 49 Cognitive Function 49 See CONTRAINDICATIONS 49 Epidermal Growth Factor Receptor 49 Aurora Kinase 49 Resistant Hypertension 49 multicenter Phase II 49 Cholesterol Drugs 49 Platelet Function 49 Potentially Fatal 49 HoFH 49 Clinical Psychology Review 49 Coronary Artery Bypass Graft 49 Antiviral Therapy 49 Zenvia Phase III 49 multicenter placebo controlled 49 CrossRef Medline 49 Patients Receiving 49 Diabetic Neuropathy 49 Sleep Disturbance 49 journal Arteriosclerosis Thrombosis 49 Scandinavian Simvastatin Survival 49 Clinical Practice Guideline 49 Cardiomyocytes 49 Sequenced Treatment Alternatives 49 fidaxomicin Phase 49 TREATMENT OF 49 Chronic Lymphocytic Leukemia 49 Vaccine Protects Against 49 Phase IIb III 49 WHEL 49 Acta Scandinavica 49 NO# [002] 49 Phase III ALLEGRO 49 label multicenter Phase 49 Lupus Nephritis 49 BizAcumen LLC 49 Mg Usa 49 Nonalcoholic Fatty Liver Disease 49 Antiplatelet 49 Chronic Lyme Disease 49 Adverse Event 49 Genetic Variations 49 Cardiac Resynchronization 49 ASCEND HF 48 S#.# [006] 48 multicentre prospective 48 Cardiovascular Risk Reduction 48 Mortality Risk 48 Prewar Intelligence 48 Telik Announces 48 Unmet Medical 48 Sustained Efficacy 48 Radiation Induced 48 Degarelix 48 Study Sheds Light 48 Breast Tumors 48 PROVENGE sipuleucel T 48 Arch Intern Med 48 Aromatase Inhibitors 48 interferon gamma 1b 48 Protease Inhibitor 48 SF #v# 48 Interferon Alfa 48 Eur Urol 48 Bipolar Disorders 48 Lowers Risk 48 Vaccine Immunology 48 Orally Active 48 Thrombotic 48 PEGINTRON TM 48 Preclinical Models 48 IMPACT DCM 48 Metabolic Disease 48 Progressive Multifocal Leukoencephalopathy 48 Non inferiority 48 Analytical Method 48 Guidelines Recommend 48 Tocilizumab 48 Bazedoxifene 48 selective modulator 48 Confirms Efficacy 48 WHIMS 48 Hematopoietic Stem Cell Transplantation 48 AACR San Antonio 48 Bronchiectasis 48 SUTENT ® 48 Exploit Code 48 neuroimaging studies 48 Skin Lesions 48 Nocturia 48 Efficacy Endpoints 48 Demonstrates Sustained 48 neuropathologic 48 Diabet Med 48 Fabry Disease 48 Receives Orphan Drug Designation 48 Myelodysplastic Syndromes 48 confirmatory clinical 48 CYP#A# CYP#D# 48 Estrogen Receptor 48 Febuxostat 48 Adjuvant Treatment 48 Phase IIIb clinical 48 ritonavir boosted 48 oral dual endothelin 48 journal Physiological 48 Lung Cancer Survival 48 Potent Antiviral Activity 48 Lacosamide 48 Technological Advances 48 ORAL Solo 48 RNAi Therapeutic 48 Researchers Uncover 48 ASCO GU 48 Protease Inhibitors 48 pharmacokinetic PK study 48 IND Application 48 Breast Cancer Cells 48 Nissen meta analysis 48 RENAL 48 Golimumab 48 PIX# [002] 48 HMG CoA reductase inhibitors 48 Blood Pressure Drugs 48 Glycemia 48 Fecal Incontinence 48 AVASTIN 48 Immunogenicity 48 Treat Parkinson Disease 48 Genetic Marker 48 CIMZIA TM certolizumab pegol 48 Acute Exacerbations 48 Proteasome 48 Genotypes 48 prospective randomized placebo 48 Coronary CTA 48 Randomized trials 48 AA Amyloidosis 48 Crit Rev 48 Metabolic Endocrinology 48 APPROVED BY 48 Urine Test 48 Elagolix 48 #:#-#,# CrossRef Medline [002] 48 Moxifloxacin 48 Stem Cell Treatment 48 Racial Ethnic Disparities 48 Podium Presentation 48 Chevrolet SILVERADO 48 Cyclooxygenase 2 48 Genetic Tests 48 Hepatitis C Infection 48 Endarterectomy 48 Chemotherapeutic Agents 48 Is Well Tolerated 48 Disease Modification 48 Peripheral Arterial 48 Pharmacodynamic 48 Health Initiative WHI 48 Cochrane Database Syst Rev 48 NICE SUGAR 48 Inflammatory Bowel Diseases 48 Ambulatory Blood Pressure 48 Cannabinoid 48 Meta analyzes 48 HCV RESPOND 2 48 Shows Promise Against 48 J Clin Oncol 48 Cognitive Abilities 48 Study Confirms 48 ASSERT 48 Radiation Exposure 48 #:#-# [006] 48 Histopathologic 48 Sorafenib HCC Assessment 47 TREATMENT FOR 47 Ramipril 47 Adverse Effects 47 Cell Proliferation 47 journal Gynecologic Oncology 47 entitled Formulary Advantages 47 Decompensated Heart Failure 47 Curr Opin 47 Pralatrexate 47 Communities ARIC Study 47 Vernakalant 47 Weight Loss Supplement 47 Intravenous Formulation 47 SANTE 47 Drug Combo 47 Solid Tumors 47 Ocular Hypertension Treatment 47 Novel Therapies 47 Occlusive Disease 47 Heart Failure Therapies 47 Diagnostic Tests 47 Phase 2a Trial 47 Denufosol 47 ACE Inhibitor 47 GW# [003] 47 iPrEx 47 ADVANCE PD 47 Depressive Symptoms 47 Demonstrate Significant 47 Ann Oncol 47 Sapacitabine 47 Pluripotent Stem Cells 47 induce orthostatic hypotension 47 Bioequivalence 47 Suicidal Behavior 47 Natalizumab 47 Gene Mutations 47 Dupuytren Contracture 47 Issues Surrounding 47 Mycophenolate Mofetil 47 Pravastatin 47 Diabetologia 47 Multiethnic Study 47 Percutaneous Tibial Nerve Stimulation 47 Whole Genome Sequencing 47 APPROVAL OF 47 Renal Artery 47 Gore REDUCE Clinical 47 Comorbidities 47 CALGB 47 Hematological 47 Sleep Duration 47 Nebulized 47 Immunohistochemical 47 TNF Blockers 47 tocilizumab 47 Brain Wiring 47 PHOSPHATE 47 Achieves Primary Endpoint 47 Treating Chronic 47 THERAPEUTICS 47 See WARNINGS 47 Vaccine Autism 47 phase IIa clinical 47 Offers Clues 47 nonrandomized 47 Alcohol Dependence 47 Phase III multicenter 47 Imaging Technique 47 Cytogenetic 47 PYY #-# 47 CONCLUSIONS 47 Tesamorelin 47 RhuDex 47 Therapy Shows Promise 47 AIR2 Trial 47 Cancer Therapies 47 Relapsed Refractory 47 Results Indicate 47 J Child Adolesc 47 Aflibercept 47 #:#-# [030] 47 Diabetic Patients 47 journal Neuropsychopharmacology 47 STEP BD 47 Clinically Significant 47 Ramelteon 47 Osteoarthritis Patients 47 CHAMPION PCI 47 Epirubicin 47 Demonstrates Statistically Significant 47 Cancer Stem Cells 47 Levetiracetam 47 #:#-# [023] 47 Wrestling Wrap Up 47 MOLECULAR 47 colesevelam HCl 47 Cigarette Smoke 47 Prostate Cancer Outcomes 47 Liraglutide Effect 47 Saxagliptin 47 chromium supplementation 47 Authorized Generics 47 Preterm Birth 47 Cognitive Dysfunction 47 pan histone deacetylase 47 CROI 47 Relieve Depression 47 EINSTEIN DVT 47 Vidaza azacitidine 47 Coagulation 47 Neuroepidemiology 47 Investigational Treatment 47 Atorvastatin Evaluation 47 serotonin norepinephrine reuptake inhibitor 47 Osteoarthritis Pain 47 TAPAS 47 Screening Trial 47 J Pediatr 47 Apixaban 47 Granted Orphan Drug 47 TAXUS IV 47 Antipsychotic 47 Am J Obstet 47 Proton Pump Inhibitor 47 Primary Endpoint 47 phase IIa 47 Zoloft sertraline 47 NESARC 47 Thyroid Function 46 Increased Incidence 46 Who Underwent 46 Pain Relievers 46 Am J Geriatr 46 Irbesartan 46 undergoing Percutaneous Coronary 46 Multicenter Automatic Defibrillator Implantation 46 Active Ulcerative Colitis 46 Pre RELAX AHF 46 Desvenlafaxine Succinate 46 Arteriosclerosis Thrombosis 46 Cervical Dysplasia 46 Soft Tissue Sarcoma 46 Nuclear Receptors 46 LibiGel ® 46 #:#-# [029] 46 Genes Linked 46 ® pioglitazone HCl 46 #:#-# [031] 46 Study Indicates 46 Combo Therapy 46 Pharmacologic 46 Gender Differences 46 clinicopathologic 46 Efficacy Results 46 Medidur TM FA 46 Illicit Drug Use 46 Phase 1a clinical 46 Hyperkalemia 46 Early Lung Cancer 46 lumiracoxib 46 Bipolar Mania 46 prucalopride 46 Dietary Modification Trial 46 Biolimus A9 46 #:#-#,# [002] 46 arzoxifene 46 MiniBooNE 46 Nonalcoholic Steatohepatitis 46 ERSPC 46 NCT# ClinicalTrials.gov 46 Cerebrovascular Diseases 46 Smallpox Vaccine 46 Hospitalization Rates 46 Serious Flaws 46 Cancer Prevention ATBC 46 Psychosomatic Research 46 Anticoagulant 46 Improve Diagnosis 46 Study Analyzes 46 riociguat 46 Eluting 46 placebo controlled studies 46 Candesartan 46 Data Indicates 46 Framingham Offspring 46 headache nasopharyngitis 46 QT Prolongation 46 Angiotensin Converting Enzyme 46 Enzyme Replacement Therapy 46 Myoblast 46 #:#-# [035] 46 Prednisone Against Refractory 46 Pharmacokinetics PK 46 Test Detects 46 Insulin Resistance Syndrome 46 #rd Annual CTRC 46 EMBO Molecular Medicine 46 Treatment Outcomes 46 Phase Ib IIa 46 J Consult Clin 46 Initiate Clinical Trial 46 Kuvan sapropterin dihydrochloride 46 ACTIVE W 46 journal Resuscitation 46 dose escalation clinical 46 Phase Ib clinical 46 Molecular Origins 46 Therapeutic Approaches 46 ACTEMRA TM 46 meta regression 46 Immune Mediated 46 Widens Probe 46 Complications Trial 46 Pregnancy Outcomes 46 Genetic Variants 46 NSABP 46 Immunologic 46 placebo controlled trials 46 Package Insert 46 Community Acquired Pneumonia 46 Acute Treatment